Azure Cell Therapies Secures Innosuisse Grant to Advance Parkinson Disease Treatment
Share this article
Azure Cell Therapies, a University of Geneva spinoff at the forefront of regenerative medicine, has been awarded a CHF 650,000 grant from Innosuisse, Switzerland’s innovation agency, to advance its pioneering cell-replacement therapies for Parkinson’s disease.
Rooted in over 20 years of research from the University of Geneva and backed by over CHF 8 million in competitive grants, Azure is developing next-generation allogeneic therapies that combine cell and genetic engineering to deliver scalable, safe, and durable treatments for neurodegenerative diseases.
We are deeply grateful to Innosuisse for their continued support. This funding marks a key milestone, enabling us to kickstart the development of our first cell therapy candidate in collaboration with Prof. Emi Nagoshi from the University of Geneva and Prof. Karl-Heinze Krause at the Fondation pour Recherche Médicale,” says Dr. Bilal Fares, CEO of Azure Cell Therapies.
This new phase of development strengthens Azure’s mission to redefine the future of medicine for Parkinson’s and other neurodegenerative disorders.
A few weeks ago, the project also got CHF 40’000 from Venture Kick.
➡️ Source: Azure Cell Therapies
📸 L to R: Dr. Bilal Fares, Cofounder and CEO, Lena Grollmus, Research Associate, Dr. Olivia Cattaneo, Science and Business Associate, Prof. Emi Nagoshi, Head of the SAB, Prof. Karl-Heinz Krause, Cofounder and CSO